Familial Mediterranean Fever Pipeline 2025: Transforming Rare Inflammatory 

DelveInsight's "Familial Mediterranean Fever Pipeline Insight 2025" report delivers extensive analysis on over 3 companies and more than 3 pipeline drugs in the Familial Mediterranean Fever treatment landscape. It includes thorough profiles of Familial Mediterranean Fever pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Familial Mediterranean Fever therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this area.

Discover the newest medications and treatment avenues in the Familial Mediterranean Fever Pipeline. Explore DelveInsight's detailed report now! @ Familial Mediterranean Fever Pipeline Outlook

Key Highlights from the Familial Mediterranean Fever Pipeline Report

• On August 27, 2025, the University of São Paulo General Hospital launched a Phase 4 randomized prospective trial with adult patients suffering from autoimmune rheumatic diseases (ARDs). Participants will get two intramuscular doses of RZV spaced six weeks apart. A control group (CG) of non-immunosuppressed individuals aged ≥50 years will be included, at a ratio of three patients to one control. ARDs patients will be randomly divided into groups P1 and P2. Both CG and P1 groups will receive the vaccine right after randomization, on Day 0 (D0) and Day 42 (D42).

• DelveInsight's Familial Mediterranean Fever Pipeline report illustrates a vibrant arena with over 3 active contributors developing more than 3 pipeline treatments for Familial Mediterranean Fever care.

• The prominent Familial Mediterranean Fever Companies include Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.

• Promising Familial Mediterranean Fever Pipeline Therapies include Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast, and others.

Gain insights into clinical trials, emerging treatments, and key companies via DelveInsight @ Familial Mediterranean Fever Treatment Drugs

Familial Mediterranean Fever Emerging Drugs Profile

• Tocilizumab: Roche Tocilizumab is a recombinant humanized monoclonal antibody that inhibits the IL-6 receptor, employed for managing inflammatory and autoimmune disorders.

The Familial Mediterranean Fever Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Familial Mediterranean Fever, including the total treatments each company is developing.

• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Familial Mediterranean Fever management.

• Familial Mediterranean Fever Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.

• Familial Mediterranean Fever Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Familial Mediterranean Fever market.

Explore innovative treatments and clinical trials in the Familial Mediterranean Fever Pipeline. Obtain DelveInsight's detailed report today! @ New Familial Mediterranean Fever Drugs

Familial Mediterranean Fever Companies Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.

Familial Mediterranean Fever pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Subcutaneous

• Intravenous

• Oral

• Parenteral

• Intramuscular

• Molecule Type

Familial Mediterranean Fever Products have been categorized under various Molecule types such as

• Small molecules

• Peptides

• Polymer

• Gene Therapy

• Monoclonal antibodies

• Product Type

Learn about emerging drugs, pipeline advancements, and key companies with DelveInsight's expert analysis @ Familial Mediterranean Fever Market Drivers and Barriers

Scope of the Familial Mediterranean Fever Pipeline Report

• Coverage- Global

• Familial Mediterranean Fever Companies- Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.

• Familial Mediterranean Fever Pipeline Therapies- Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast, and others.

• Familial Mediterranean Fever Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Familial Mediterranean Fever Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's comprehensive pipeline report now! @ Familial Mediterranean Fever Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction

2. Executive Summary

3. Familial Mediterranean Fever: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Familial Mediterranean Fever - DelveInsight's Analytical Perspective

7. In-depth Commercial Assessment

8. Familial Mediterranean Fever Collaboration Deals

9. Late Stage Products (Phase III)

10. Drug profiles in the detailed report.....

11. Mid Stage Products (Phase II)

12. Tocilizumab: Roche

13. Drug profiles in the detailed report.....

14. Pre-clinical and Discovery Stage Products

15. Drug profiles in the detailed report.....

16. Inactive Products

17. Familial Mediterranean Fever Key Companies

18. Familial Mediterranean Fever Key Products

19. Familial Mediterranean Fever- Unmet Needs

20. Familial Mediterranean Fever- Market Drivers and Barriers

21. Familial Mediterranean Fever- Future Perspectives and Conclusion

22. Familial Mediterranean Fever Analyst Views

23. Familial Mediterranean Fever Key Companies

24. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our team of seasoned industry professionals and deep expertise in life sciences and healthcare deliver tailored research services and insights globally. Connect with us for accurate, timely data to stay competitive.

Contact Us

Kanishk

kkumar@delveinsight.com